21
Participants
Start Date
March 1, 2021
Primary Completion Date
March 20, 2021
Study Completion Date
March 20, 2021
Four naloxone nasal spray doses (1 every 2.5 min)
Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min
Four naloxone nasal spray doses (2 every 2.5 min)
Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
Two naloxone nasal spray doses (1 every 2.5 min)
Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
Spaulding Clinical Research, West Bend
Spaulding Clinical Research LLC
OTHER
Food and Drug Administration (FDA)
FED